Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xeris Pharmaceuticals Inc
(NQ:
XERS
)
2.010
+0.010 (+0.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xeris Pharmaceuticals Inc
< Previous
1
2
3
Next >
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 17, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
September 14, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
September 01, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
August 30, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia
August 23, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Strengthens Its Patent Estate
August 19, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®
August 13, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
August 11, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
August 05, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
July 29, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
July 29, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success
July 28, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
July 19, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 02, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, INSW, LMNX, XERS; Shareholders are Encouraged to Contact the Firm
May 27, 2021
NEW YORK, NY / ACCESSWIRE / May 27, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kansas City Southern (NYSE:KSU) concerning...
From
Halper Sadeh LLP
Via
AccessWire
Topics
Fraud
Exposures
Legal
Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XERS
May 24, 2021
From
Halper Sadeh LLP
Via
Business Wire
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 24, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 24, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
May 13, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals to Webcast Upcoming Presentations
May 10, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
May 06, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
May 06, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
NASDAQ:XERS Shareholder Notice: Investigation over Potential Wrongdoing at Xeris Pharmaceuticals, Inc.
May 05, 2021
San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Xeris Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
April 29, 2021
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.